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The invaluable comments from Professor Wiwanitkit1 echo
the prudence of the authors on the topic of psychiatric
symptoms during oseltamivir treatment. Oseltamivir is rec-
ommended for the prophylaxis and treatment of influenza2; by
no means do we argue against its usage. Instead, we have
suggested its vigilant prescription and have conspicuously
emphasized its significance in psychiatric patients at risk of or
infected by influenza, as stated in our abstract, “Influenza
treatment and prophylaxis with oseltamivir are critically
important in reducing the morbidity and mortality of patients
in chronic psychiatric facilities.”3
The most important point we intended to share with the
professional community was that we should be cautious about
possible exacerbations of psychiatric symptoms when pre-
scribing oseltamivir for prophylaxis or treatment among
patients who were already diagnosed with a mental illness, at
least until more definite evidence centering on psychiatric
patients emerges. This is particularly noteworthy because much
of the current literature regarding the safety of oseltamivir
(especially in terms of neuropsychiatric problems) derives
collectively from (1) a study that was not aiming for directly
comparing the difference between individuals with or without
baseline psychiatric disorder4; (2) a study that did not explicitly
state whether psychiatric patients were included or not5; (3) a
mini-review that focused more on the viral resistance to neu-
raminidase inhibitor than on its side effects6; and (4) a very
comprehensive and thorough review in 20087 and its updated
version in 20128 that were intended to target influenza patients
in general rather than psychiatric patients specifically. In total,
we are uncertain whether this evidence collectively may be
sufficient to draw the final conclusion on the safety profile of
oseltamivir among patients with mental illness. Regarding the
possible mechanisms of oseltamivir-induced neuropsychiatric
symptoms, previous animal studies have suggested that osel-
tamivir might influence dopaminergic neurotransmission.9,10
Admittedly, the adverse reactions to oseltamivir treatment
may or may not be the same between animal and human
patients, as well as between patients with or without an estab-
lished psychiatric diagnosis. Therefore, additional human
studies are warranted as highlighted in our paper.
Finally, other than simply attributing our observations to a
coincidence, we enumerated several possibilities in ourx.doi.org/10.1016/j.jcma.2015.06.001
901/Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Assdiscussion as the potential cause of the psychiatric instability
in addition to oseltamivir treatment, including influenza
infection itself with or without encephalitis and the reduction
of antipsychotic dosage. By meticulously examining these
possible factors, which are inherently impossible to be either
confirmed or refuted definitively by our case report, we hope
to gain a more comprehensive perspective and initiate an
active dialog regarding the proper use of oseltamivir in
patients with an established psychiatric diagnosis.
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